GREENLAND MINES LTD Financial and Nonfinancial Liabilities, Fair Value Disclosure
GREENLAND MINES LTD (GRML) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $5.90 million as of 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:LiabilitiesFairValueDisclosure · last filed 2026-08-17
- 2026-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $5.90M.
- 2026-03-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $7.71M.
- 2025-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $53.00K.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $5.90M 10-Q · filed 2026-08-17 |
| 2026-03-31 | $7.71M 10-Q/A · filed 2026-08-14 |
| 2025-12-31 | $53.00K 10-Q · filed 2026-08-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |